INVA Innoviva, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$21.58

Period return

+1.84 (+9.32%)

Volume

589.5K

2026-07-21O $21.19 H $21.72 L $21.19 C $21.58MA5 $21.73MA20 $22.39MA60 $22.47MA120 $22.56

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 05.Highin 15 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 26.LowBUY2 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.03%
2026. 05. 07.LowBUY3 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 02. 26.LowBUY5 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 02. 17.MediumBUY5 months ago
BTIG: Buy
US analyst rating / recommendation change.
2025. 12. 16.LowBUY7 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2025. 11. 06.LowBUY9 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2025. 09. 30.MediumSELL10 months ago
Goldman Sachs: Sell
US analyst rating / recommendation change.
2025. 08. 11.MediumBUY11 months ago
Oppenheimer: Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $35.5 · 4 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 05.	After market close (AMC)	$0.5	—	—	$110.93M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.74	—	—	$88.63M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$0.05	—	—	$266.91M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$0.03	—	—	$177.4M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,484,264	$34.58M	0.03%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	839,865	$16.79M	0.03%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	113,805	$2.27M	0.00%	—	New position

Innoviva, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 26.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 05. 07.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 02. 26.	BTIG	—	Maintain	Buy → Buy	—	BTIG: Buy
2026. 02. 17.	BTIG	—	Initiate coverage	— → Buy	—	BTIG: Buy
2025. 12. 16.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2025. 11. 06.	Cantor Fitzgerald	—	Maintain	Overweight → Overweight	—	Cantor Fitzgerald: Overweight